A Phase 3 interventional study of Placebo and Ramucirumab DP (IMC-1121B) in Hepatocellular Carcinoma, sponsored by Eli Lilly and Company. Completed at 146 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-28.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company — none open to participants now, none under way, none of them phase 3. Carcinoma, Hepatocellular · Eli Lilly and Company.
Among the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company, this one has the largest enrollment, is the only one that started in 2010, is one of 2 in phase 3, and was the 4th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.
Browse Carcinoma, Hepatocellular studies →None of the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company is open now. The open studies under Carcinoma, Hepatocellular, anywhere →
Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 2
First in 2008; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 565 is above the median of 54 across 2,619 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 47 across the 13 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3 multicenter, randomized study evaluating the safety and efficacy of ramucirumab DP plus BSC as a double-blind, placebo-controlled (placebo plus BSC) comparison.
Approximately 544 participants, at least 18 years of age, with Child-Pugh score \< 7 and diagnosed with hepatocellular carcinoma will be randomized. Participants must have received sorafenib as first-line systemic treatment for hepatocellular carcinoma (HCC), and must have discontinued sorafenib prior to entering the study.
Hypothesis: This sample size will allow differentiation of the expected increase in median overall survival (OS), from 8 months in the placebo arm to 10.67 months in the ramucirumab arm.
Upon registration and completion of screening procedures, eligible participants with HCC who have disease progression during or following first-line therapy with sorafenib, or were intolerant to this agent, will be randomized to receive either ramucirumab DP or placebo.
The treatment regimen will be continued until radiographic or symptomatic progression, the development of unacceptable toxicity, noncompliance or withdrawal of consent by the participant, or investigator decision.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Previously treated with sorafenib and has discontinued sorafenib treatment at least 14 days prior to randomization. Participants may have experienced:
Adequate Organ Function defined as:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Ramucirumab DP (IMC-1121B) · Other: BSC
Biological: Placebo · Other: BSC
8 mg/kg IV every 2 weeks
8 milligrams/kilogram (mg/kg) intravenous (IV) every 2 weeks
Also known as: IMC-1121B, LY3009806
Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.
Overall Survival (OS)
OS was defined as the time from the date of randomization to the date of death from any cause. Participants who were alive at the end of the follow-up period or were lost to follow-up were censored on the last date the participant was known to be alive.
Time frame: Randomization to death from any cause (up to 37 months)
Progression-Free Survival (PFS)
PFS was defined as time from date of randomization until date of objectively determined progressive disease (PD) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 or death from any cause. PD was defined as ≥20% increase in sum of diameters (SOD) of target lesions, taking as reference smallest sum on study (including baseline sum if it was smallest). Sum must show a ≥5 millimeter (mm) increase. Appearance of ≥1 new lesions and unequivocal progression of existing non-target lesions were considered progression. In primary analysis, participants alive and without PD were censored at day of last adequate tumor assessment; progression or deaths without progression occurring immediately after ≥2 missed tumor assessments, were censored at day of the last adequate tumor assessment prior to missing assessments; participants who began new anticancer therapy were censored at day of the last adequate tumor assessment prior to start of new anticancer therapy.
Time frame: Randomization to PD (up to 36 months)
Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]
ORR was defined, using RECIST v1.1 criteria, as the percentage of participants who achieved a best overall response of CR or PR. CR was defined as the disappearance of all lesions and any intratumor arterial enhancement in target lesions, the normalization of the tumor marker level and all lymph nodes short axis reduced to \<10 mm. PR was defined as ≥30% decrease in the SOD of target lesions, including the short axes of any target lymph nodes, taking as reference the baseline SOD of target lesions, no new lesions and stable nontarget lesions. Percentage of participants was calculated as: (number of participants with CR or PR / number of participants randomized) \* 100.
Time frame: Baseline to the date of first evidence of confirmed CR or PR (up to 37 months)
Time to Radiographic Progression (TTP)
TTP was defined as the time from randomization to the first radiographically documented PD. PD was defined, using RECIST v1.1 criteria, as ≥20% increase in SOD of target lesions, taking as reference smallest sum on study (including baseline sum if it was the smallest). Sum must show an absolute increase of ≥5 mm. Appearance of ≥1 new lesions and unequivocal progression of existing non-target lesions were considered progression. Participants without PD were censored at the day of the last adequate tumor assessment. Progression occurred immediately after ≥2 missed tumor assessments and were censored at the day of the last adequate tumor assessment prior to the missing assessments. Participants who began new anticancer therapy were censored at the day of their last adequate tumor assessment prior to start of new anticancer therapy.
Time frame: Randomization to PD (up to 36 months)
Change From Baseline in the Functional Assessment of Cancer Therapy (FACT) Hepatobiliary Symptom Index-8 (FHSI-8)
The FHSI-8 is a self-administered 8-item questionnaire that measures a participant's symptoms in the domains of jaundice, stomach pain/discomfort weight loss, and fatigue. Participants rated each item on a 5-point scale from 0 (not at all) to 4 (very much). Item scores were calculated as outlined in the FACIT manual. FHSI-8 total score was the sum of each item's score with a total score ranging from 0 (highly symptomatic) to 32 (asymptomatic).
Time frame: Baseline, Prior to infusion on Day 1 of Cycle 4, Cycle 10, and Cycle 16 (14-day cycles), and end of treatment (up to 34 months)
Change From Baseline in European Quality of Life Questionnaire-5 Dimensions (EQ-5D) Health State Score
The EQ-5D is a self-reported, 5-dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) questionnaire related to the participant's current health state. Each question was scored using a 3 level scale (no problems, some problems, or extreme problems). EQ-5D health state was defined by combining responses from each of the 5 dimensions into a weighted health-state index score according to the United Kingdom (UK) population based algorithm where 0 = death and 1 = perfect health.
Time frame: Baseline, Prior to infusion on Day 1 of Cycle 4, Cycle 10, and Cycle 16 (14-day cycles), end of treatment (up to 34 months)
Number of Participants With Adverse Events (AEs) and the Number of Participants Who Died
The number of participants with serious AEs (SAEs), other non-serious AEs and participants who died. A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
Time frame: Baseline to study completion (up to 37 months)
Maximum Concentration (Cmax) of Ramucirumab, Cycle 1
Time frame: 1 hour following the completion of Cycle 1 (14-day cycle) infusion
Cmax of Ramucirumab, Cycle 4
Time frame: 1 hour following completion of Cycle 4 (14-day cycles) infusion
Cmax of Ramucirumab, Cycle 7
Time frame: 1 hour following completion of Cycle 7 (14-day cycles) infusion
Number of Participants With Treatment Emergent Positive Anti-Ramucirumab Response [Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)]
Participants were considered positive for anti-ramucirumab antibodies \[anti-drug antibodies (ADA)\] if the post-treatment sample had an increase of at least 4-fold in titer from the pretreatment values. If the pretreatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence of ADA.
Time frame: Prior to treatment and 1 hour post end of infusion for Cycles 1, 4 and 7 (14-day cycles)
| Milestone | Ramucirumab (IMC-1121B) + BSC | Placebo + BSC |
|---|---|---|
| Started | 283 | 282 |
| Received at least 1 dose of study drug | 277 | 276 |
| Completed | 265 | 268 |
| Not completed | 18 | 14 |
| Withdrew: Lost to follow-up | 5 | 6 |
| Withdrew: Withdrawal by subject | 13 | 8 |
OS was defined as the time from the date of randomization to the date of death from any cause. Participants who were alive at the end of the follow-up period or were lost to follow-up were censored on the last date the participant was known to be alive.
| months | Ramucirumab (IMC-1121B) + BSC | Placebo + BSC |
|---|---|---|
| Overall Survival (OS) | 9.17 (8.05 to 10.64) | 7.62 (6.01 to 9.33) |
PFS was defined as time from date of randomization until date of objectively determined progressive disease (PD) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 or death from any cause. PD was defined as ≥20% increase in sum of diameters (SOD) of target lesions, taking as reference smallest sum on study (including baseline sum if it was smallest). Sum must show a ≥5 millimeter (mm) increase. Appearance of ≥1 new lesions and unequivocal progression of existing non-target lesions were considered progression. In primary analysis, participants alive and without PD were censored at day of last adequate tumor assessment; progression or deaths without progression occurring immediately after ≥2 missed tumor assessments, were censored at day of the last adequate tumor assessment prior to missing assessments; participants who began new anticancer therapy were censored at day of the last adequate tumor assessment prior to start of new anticancer therapy.
| months | Ramucirumab (IMC-1121B) + BSC | Placebo + BSC |
|---|---|---|
| Progression-Free Survival (PFS) | 2.79 (2.69 to 3.94) | 2.10 (1.58 to 2.69) |
ORR was defined, using RECIST v1.1 criteria, as the percentage of participants who achieved a best overall response of CR or PR. CR was defined as the disappearance of all lesions and any intratumor arterial enhancement in target lesions, the normalization of the tumor marker level and all lymph nodes short axis reduced to \<10 mm. PR was defined as ≥30% decrease in the SOD of target lesions, including the short axes of any target lymph nodes, taking as reference the baseline SOD of target lesions, no new lesions and stable nontarget lesions. Percentage of participants was calculated as: (number of participants with CR or PR / number of participants randomized) \* 100.
| percentage of participants | Ramucirumab (IMC-1121B) + BSC | Placebo + BSC |
|---|---|---|
| Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] | 7.1 (4.6 to 10.7) | 0.7 (0.2 to 2.5) |
TTP was defined as the time from randomization to the first radiographically documented PD. PD was defined, using RECIST v1.1 criteria, as ≥20% increase in SOD of target lesions, taking as reference smallest sum on study (including baseline sum if it was the smallest). Sum must show an absolute increase of ≥5 mm. Appearance of ≥1 new lesions and unequivocal progression of existing non-target lesions were considered progression. Participants without PD were censored at the day of the last adequate tumor assessment. Progression occurred immediately after ≥2 missed tumor assessments and were censored at the day of the last adequate tumor assessment prior to the missing assessments. Participants who began new anticancer therapy were censored at the day of their last adequate tumor assessment prior to start of new anticancer therapy.
| months | Ramucirumab (IMC-1121B) + BSC | Placebo + BSC |
|---|---|---|
| Time to Radiographic Progression (TTP) | 3.48 (2.76 to 4.47) | 2.63 (1.58 to 2.76) |
The FHSI-8 is a self-administered 8-item questionnaire that measures a participant's symptoms in the domains of jaundice, stomach pain/discomfort weight loss, and fatigue. Participants rated each item on a 5-point scale from 0 (not at all) to 4 (very much). Item scores were calculated as outlined in the FACIT manual. FHSI-8 total score was the sum of each item's score with a total score ranging from 0 (highly symptomatic) to 32 (asymptomatic).
| units on a scale | Ramucirumab (IMC-1121B) + BSC | Placebo + BSC |
|---|---|---|
| Cycle 4 (n=166, 147) | -1.26 ± 3.164 | -0.81 ± 4.623 |
| Cycle 10 (n=70, 45) | -1.28 ± 3.989 | -0.01 ± 4.378 |
| Cycle 16 (n=47, 24) | -0.97 ± 4.095 | 0.75 ± 3.768 |
| End of Treatment (n=169, 199) | -2.44 ± 5.561 | -2.86 ± 5.618 |
The EQ-5D is a self-reported, 5-dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) questionnaire related to the participant's current health state. Each question was scored using a 3 level scale (no problems, some problems, or extreme problems). EQ-5D health state was defined by combining responses from each of the 5 dimensions into a weighted health-state index score according to the United Kingdom (UK) population based algorithm where 0 = death and 1 = perfect health.
| units on a scale | Ramucirumab (IMC-1121B) + BSC | Placebo + BSC |
|---|---|---|
| Cycle 4 (n=166, 145) | -0.038 ± 0.189 | -0.046 ± 0.245 |
| Cycle 10 (n=71, 45) | -0.054 ± 0.212 | 0.003 ± 0.148 |
| Cycle 16 (n=47, 25) | -0.062 ± 0.214 | -0.012 ± 0.085 |
| End of Treatment (n=166, 190) | -0.129 ± 0.290 | -0.144 ± 0.280 |
The number of participants with serious AEs (SAEs), other non-serious AEs and participants who died. A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
| participants | Ramucirumab (IMC-1121B) + BSC | Placebo + BSC |
|---|---|---|
| SAEs | 123 | 92 |
| Other Non-SAEs | 254 | 235 |
| Died | 215 | 220 |
| micrograms/milliliter (µg/mL) | Ramucirumab (IMC-1121B) + BSC |
|---|---|
| Maximum Concentration (Cmax) of Ramucirumab, Cycle 1 | 149.6 ± 36.9 |
| µg/mL | Ramucirumab (IMC-1121B) + BSC |
|---|---|
| Cmax of Ramucirumab, Cycle 4 | 189.5 ± 39.1 |
| µg/mL | Ramucirumab (IMC-1121B) + BSC |
|---|---|
| Cmax of Ramucirumab, Cycle 7 | 184.4 ± 56.3 |
Participants were considered positive for anti-ramucirumab antibodies \[anti-drug antibodies (ADA)\] if the post-treatment sample had an increase of at least 4-fold in titer from the pretreatment values. If the pretreatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence of ADA.
| participants | Ramucirumab (IMC-1121B) + BSC | Placebo + BSC |
|---|---|---|
| Number of Participants With Treatment Emergent Positive Anti-Ramucirumab Response [Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)] | 10 | 7 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ramucirumab (IMC-1121B) + BSC | — | 124/277 (44.8%) | 254/277 (91.7%) |
| Placebo + BSC | — | 92/276 (33.3%) | 235/276 (85.1%) |
| Event | Ramucirumab (IMC-1121B) + BSC | Placebo + BSC |
|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 23/277 | 16/276 |
| Hepatic encephalopathyNervous system disorders | 12/277 | 1/276 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 4/277 | 10/276 |
| Abdominal painGastrointestinal disorders | 6/277 | 9/276 |
| General physical health deteriorationGeneral disorders | 9/277 | 3/276 |
| AscitesGastrointestinal disorders | 8/277 | 3/276 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 7/277 | 0/276 |
| PyrexiaGeneral disorders | 7/277 | 3/276 |
| Hepatic failureHepatobiliary disorders | 6/277 | 5/276 |
| CholangitisHepatobiliary disorders | 5/277 | 1/276 |
| Event | Ramucirumab (IMC-1121B) + BSC | Placebo + BSC |
|---|---|---|
| Oedema peripheralGeneral disorders | 100/277 | 50/276 |
| AscitesGastrointestinal disorders | 72/277 | 40/276 |
| FatigueGeneral disorders | 66/277 | 60/276 |
| Decreased appetiteMetabolism and nutrition disorders | 59/277 | 50/276 |
| Abdominal painGastrointestinal disorders | 45/277 | 58/276 |
| HypertensionVascular disorders | 55/277 | 20/276 |
| HeadacheNervous system disorders | 53/277 | 15/276 |
| NauseaGastrointestinal disorders | 52/277 | 52/276 |
| DiarrhoeaGastrointestinal disorders | 50/277 | 38/276 |
| AstheniaGeneral disorders | 50/277 | 36/276 |
All randomized participants.
| Age, Continuous(years) | Ramucirumab (IMC-1121B) + BSC | Placebo + BSC | Total |
|---|---|---|---|
| Mean | 62.9 ± 11.56 | 62.5 ± 11.10 | 62.7 ± 11.33 |
| Age, Customized(participants) | Ramucirumab (IMC-1121B) + BSC | Placebo + BSC | Total |
|---|---|---|---|
| <65 years | 150 | 162 | 312 |
| ≥65 years | 133 | 120 | 253 |
| Sex: Female, Male(Participants) | Ramucirumab (IMC-1121B) + BSC | Placebo + BSC | Total |
|---|---|---|---|
| Female | 47 | 40 | 87 |
| Male | 236 | 242 | 478 |
| Ethnicity (NIH/OMB)(Participants) | Ramucirumab (IMC-1121B) + BSC | Placebo + BSC | Total |
|---|---|---|---|
| Hispanic or Latino | 23 | 20 | 43 |
| Not Hispanic or Latino | 253 | 260 | 513 |
| Unknown or Not Reported | 7 | 2 | 9 |
| Race (NIH/OMB)(Participants) | Ramucirumab (IMC-1121B) + BSC | Placebo + BSC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 131 | 135 | 266 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 3 | 8 |
| White | 139 | 137 | 276 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 8 | 7 | 15 |
| Region of Enrollment(participants) | Ramucirumab (IMC-1121B) + BSC | Placebo + BSC | Total |
|---|---|---|---|
| United States | 17 | 20 | 37 |
| Portugal | 0 | 2 | 2 |
| Philippines | 1 | 0 | 1 |
| Taiwan | 33 | 25 | 58 |
| Hong Kong | 14 | 10 | 24 |
| Spain | 9 | 12 | 21 |
| Thailand | 5 | 1 | 6 |
| Israel | 1 | 1 | 2 |
| Switzerland | 1 | 1 | 2 |
| Italy | 33 | 18 | 51 |
| France | 32 | 27 | 59 |
| Australia | 3 | 8 | 11 |
| Netherlands | 2 | 1 | 3 |
| Korea, Republic of | 28 | 42 | 70 |
| Finland | 0 | 3 | 3 |
| Austria | 4 | 4 | 8 |
| Czech Republic | 11 | 9 | 20 |
| Hungary | 1 | 0 | 1 |
| Canada | 0 | 1 | 1 |
| Belgium | 3 | 5 | 8 |
| Brazil | 15 | 12 | 27 |
| Romania | 3 | 4 | 7 |
| Bulgaria | 2 | 4 | 6 |
| Germany | 19 | 21 | 40 |
| Norway | 1 | 1 | 2 |
| Japan | 45 | 48 | 93 |
| Sweden | 0 | 2 | 2 |
Showing the first 100 of 146 sites across 27 countries. Choose a country and city above to see the rest.
The record gives a start of Oct 2010, a primary completion of Mar 2014 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 1 year after primary completion. A results delay was requested in Jul 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramucirumab